Targeting Inflammation and Oxidative Stress in Atrial Fibrillation: Role of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibition with Statins
Antioxidants and Redox Signaling2013Vol. 20(8), pp. 1268–1285
Citations Over TimeTop 10% of 2013 papers
Abstract
A better understanding of the mechanisms underpinning the putative antiarrhythmic effects of statins may afford tailoring AF treatment to specific clinical settings and patient's subgroups. Large-scale randomized clinical trials are needed to support the indication of statin therapy solely on the basis of AF prevention.
Related Papers
- → Stroke prevention in atrial fibrillation(2016)463 cited
- → Midterm survival in patients treated for atrial fibrillation: A propensity-matched comparison to patients without a history of atrial fibrillation(2012)132 cited
- → Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: retrospective cohort studies(2018)52 cited
- → Incidence, clinical features and outcomes of atrial fibrillation and stroke in Qatar(2019)19 cited
- → Clinical Characteristics, Management, and Control of Permanent vs. Nonpermanent Atrial Fibrillation: Insights from the RealiseAF Survey(2014)11 cited